Breaking News, Financial News

Societal CDMO 3Q Revenue up 19%

During the quarter company signed $8.2 million in new and expanded project agreements.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Societal CDMO  3Q Revenue: $21.6 million (+19%) 3Q Loss: $3.3 million (loss of $3.5 million 3Q21) YTD Revenues: $65.9 million (+24%) YTD Loss: $10.7 million (loss of $9.0 million YTD21) Comments: During the quarter, the company signed $8.2 million in new and expanded project agreements. This represents the highest number of new contracts signed in any quarter by the company since becoming an independent and dedicated CDMO. The new projects span clinical trial services, analytical method, ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters